abstract |
The present invention relates to a compound for use in a method for treating a procalcitonin mediated systemic inflammation associated disease, particularly sepsis, wherein the compound is an antagonist or inhibitor of CRLR, RAMP1, RAMP2, RAMP3, or RCP. |